Corbus presents Phase 1b CANYON-1 data for CRB-913 at ObesityWeek 2026
Oral CB1 inverse agonist produced 5% placebo-adjusted weight loss at 60 mg over 12 weeks, with discontinuations due to adverse events at 8.3% across cohorts.
Corbus Pharmaceuticals Holdings announced on November 16, 2026 that additional data from its CANYON-1 Phase 1b obesity trial of CRB-913 were presented in a poster at ObesityWeek 2026 in Washington, D.C., held November 14 to 17, 2026.
The trial was a 16-week, double-blind, placebo-controlled, dose-ranging study that enrolled 254 obese, non-diabetic adult participants at 15 investigational sites in the United States (NCT07310901)1. It tested three CRB-913 cohorts of 20 mg, 40 mg, and 60 mg dosed orally once daily, as well as a placebo cohort (randomization ratio of 1:1:1:1)1, with participants dosed for 12 weeks and followed for an additional 4 weeks1.
On efficacy, the LS mean placebo-adjusted weight loss at week 12 was 2.8% for 20 mg, 3.3% for 40 mg, and 5.0% for 60 mg, each with p-values versus placebo below 0.00011. Waist circumference and BMI also showed statistically significant reductions at all three doses. Among completers at the 60 mg dose, all participants who completed the study lost weight, with 44.4% losing at least 5.0% from baseline, 6.7% losing more than 7.5%, and the highest recorded loss reaching 13.4% from baseline1.
On safety, the treatment discontinuation rate due to adverse events across all study cohorts was 8.3%, which the company said is in line with published GLP-1 data1. Psychiatric adverse events were infrequent and mostly mild, and all resolved, with no serious or severe psychiatric AEs reported1. Gastrointestinal adverse events, including vomiting, nausea, and constipation, occurred at lower rates and were less severe than those reported in published studies of oral GLP-1s, with treatment discontinuations due to gastrointestinal AEs occurring in only three participants1.
Looking ahead, Corbus plans to engage with the FDA to discuss the data and development plans for CRB-913, and is also evaluating the drug's potential in combination with GLP-1 therapies1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.